Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
101k bid at .01 and 128k bid at .009, you can sell all 200k at a minimum average of $0.0095 if you put a limit sell order in at .009. Many shares will likely sell higher because there is a 10k share bid at .014 and probably other hidden bids.
We would all love to see you put your money where your mouth is but we know you wont. I remember personally telling you a handful of times that you could sell for a big profit when it was over .05-.06 so if you choose to hold dont complain and blame others but here you are day after day still blaming everybody but yourself for your own decisions...You could have doubled your money (or even more) at many different times but you were too greedy and yet you still blame the company and other posters for you being "down". It's shameful...
https://www.otcmarkets.com/stock/ALRTF/overview
Please use google before posting false information. They don’t replace insulin
You clearly have no understanding of diabetes much less the diabetes market. There is endless information, clinical studies, and KOL opinions (not to mention common sense) all stating how much better CGMs are then BGMs, nobody thinks BGMs are better except you apparently. The issue is cost, not CGMs. Diabetics already have tons of healthcare related expenses like doctor/hospital visits, insulin, and BGM testing supplies, they can't afford another $25-$300 a month depending on copay for CGMs. If ALRT is able to sell 2 CGMs (a month supply) at the same price as monthly BGM testing supplies they will easily take over the market. No government, insurer, HCP, or uninsured person is going to pay 5x-10x the price for a CGM from Abbott or Dexcom. Not to mention it opens up CGMs for the 530 million+ other diabetics not using Abbott or Dexcom. That is also just taking into account the hardware aspect, they have proven the value of their software as well.
Why do you think diabetics don't use CGMs? Because they enjoy pricking their fingers to draw blood to check glucose 3+ times a day? You don't think that is painful? You don't think you miss a ton of data checking 3+ times a day vs a CGM checking every 3-5 minutes for 14 days? So why do you think only 7 million out of 537 million diabetics are using CGMs?
The problem with ALRTF stock isn't ALRT, it's whiny shareholders who know nothing about the company or the market the company is in.
There are 537,000,000 diabetics in the world and you are worried about Abbott having 6 million users? The fact that Abbott only has a 1% of the market share and they are the leading CGM manufacturer (with only one competitor, Dexcom) tells me there is something desperately wrong with how they are selling CGMs. The ALRT investor presentation on their website says on page 13 the biggest barrier is cost so ALRT is making an ultra low cost CGM paired with their diabetes software. Makes complete sense to me.
Not to mention just 5 minutes of research on diabetes and CGMs will turn up a ton of diabetic message boards and forums talking about the problem of cost and copays, and that is just here in the US and Europe. It's much worse elsewhere.
https://diabetesatlas.org/
Great post, I couldn't agree more. One other thing I would add to what you said is that it costs the company money to trade on the OTC board and even more money to trade on OTC.QB, not just from OTC fees but all the costs of filings and preparing filings and audits and all that stuff. So instead of diluting the company into the ground to pay for operating costs, Mr. Chan and his family have not only funded the company but also continues to pay to keep ALRTF trading. That speaks volumes for both the character of Mr. Chan and the future of the company IMO.
I don't check this board often or post here due to the same tired posts from negative people who refuse to take responsibility for their own investing decisions, but rest assured I am here and very bullish. I don't care what the share price does day to day or month to month because this is a lottery ticket investment not a day trade for me. But I like our odds. I like that we have two ponies in the race, the pet CGM which is much needed according to veterinarians I have talked to and the human diabetes platform which we know from the clinical trials is also needed because it works to reduce A1C. Again, I like our odds.
$4k traded today, somebody is tax loss selling their position IMO. Nice opportunity for anybody with free funds
They have previously said NYSE which makes sense because it has easier requirements then NASDAQ
A press release would have been nice, but its good to see the update.
$ALRTF just released a new investor deck, worth looking at (https://www.alrt.com/documents/ALRT%20Web%20Deck%202023-Q4.pdf). They launched the first and only CGM for diabetic pets and are developing an ultra low cost CGM for diabetic humans. Targeting an uplisting in Q1-Q2 with only 120 million share float and never any dilution since CEO has funded the company himself.
I know you all don't usually discuss microcaps but $ALRTF is a fully reporting OTC.QB stock that just launched the first and only CGM for diabetic dogs and cats, they are also developing an ultra low cost CGM for humans and plan on uplisting in Q1-Q2. They just released a new investor presentation that is worth checking out (https://www.alrt.com/documents/ALRT%20Web%20Deck%202023-Q4.pdf), the float is only around 120 million shares and there has never been dilution because the CEO and his family have fully funded the company.
The timeline is pretty exciting to see, positive cashflow in Q1, uplisting in Q1-Q2, Human CGM testing in Q2-Q3, a major study in December and a pet food partnership in Q1-Q2. Not to mention a US relaunch in January and it looks like they are going to the two largest veterinary conferences in January and February. I wonder if they will have their own booth or if they will do something jointly with Covetrus? I see Covetrus registered for both but I dont see ALRT or GluCurve registered yet on either floorplan...
New Q4 investor presentation on ALRT's website, I think it was posted this morning, I didn't see it early this week: https://www.alrt.com/documents/ALRT%20Web%20Deck%202023-Q4.pdf
www.GluCurve.ca is live, I believe it previously said coming soon.
ALRTF worth checking out, news just released of patent grant for predictive A1C, this is a big deal in the diabetes world. They are also relaunching the GluCurve Pet CGM which is the first and only CGM for diabetic pets. www.alrt.com or www.GluCurve.com. $0.03 a share and never any dilution in company history, CEO self funds the company
ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
NEWS PROVIDED BY
ALR TECHNOLOGIES SG LTD
28 Sep, 2023, 08:28 ET
SHARE THIS ARTICLE
SINGAPORE, Sept. 28, 2023 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCQB: ALRTF), a diabetes management company, announces the patent application titled Method and System of Monitoring a Diabetes Treatment Plan ("Predictive A1c") has been granted in Singapore and has received notice of allowance in the United States.
Predictive A1c is the Company's cornerstone, the first of its kind U.S Food & Drug Administration ("FDA") cleared Diabetes Management Solution that shifts patient self-management to active patient management while providing best practice guidelines and ensuring adherence to care plans. Predictive A1c is owned by Sidney Chan, Chairman and CEO of ALRT. The Company has the right to utilize Predictive A1c pursuant to an informal license with Mr. Chan and expects to acquire the intellectual property in the next 12 months. Final steps have been taken in the United States Patent and Trademark Office for issuance of the US patent for Predictive A1c, and the US patent is expected to grant in the coming weeks. The Company expects Predictive A1c patent applications submitted in other jurisdictions to advance to grant in 2024.
Additionally, ALRT announces the successful completion of its 24-week study led by Singapore General Hospital ("SGH"). A total of 25 insulin-treated patients with type 2 diabetes mellitus were enrolled into the ALRT Diabetes Solution platform. The patients performed twice daily capillary blood glucose checks and weekly glucometer uploads. The platform then provided insulin dose suggestions and alerts to the physicians. All patients experienced a mean drop of 1.2 percent in glycated hemoglobin (HbA1c). The findings from the study validated the significant value that ALRT Diabetes Solution may potentially bring to patients and health care providers. The results were presented at the recent International Diabetes Federation Western Pacific Congress 2023 in Kyoto, Japan, and are expected to be published in the future.
"We are pleased to see the continued success of the ALRT Diabetes Solution from the outcome of this SGH study that replicated the results of our previous clinical trials in Canada and Kansas City, all of which have resulted in a 1.2 percent drop in mean A1c," commented Sidney Chan, Chairman and CEO of ALRT. "The successful conclusion of this study gives ALRT the clinical evidence needed to continue forwarding our efforts in deploying ALRT Diabetes Solution in ASEAN territories. On top of that, receiving the patent grant for Predictive A1c protects our clinically proven effective diabetes management system against would be competitors while securing our competitive advantage over other software platforms."
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA- cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate
dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT and the GluCurve Pet CGM can be found at www.alrt.com and https://www.glucurve.com/Index.
ALRTF worth checking out, news just released of patent grant for predictive A1C, this is a big deal in the diabetes world. They are also relaunching the GluCurve Pet CGM which is the first and only CGM for diabetic pets. www.alrt.com or www.GluCurve.com. $0.03 a share and never any dilution in company history, CEO self funds the company
ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
NEWS PROVIDED BY
ALR TECHNOLOGIES SG LTD
28 Sep, 2023, 08:28 ET
SHARE THIS ARTICLE
SINGAPORE, Sept. 28, 2023 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCQB: ALRTF), a diabetes management company, announces the patent application titled Method and System of Monitoring a Diabetes Treatment Plan ("Predictive A1c") has been granted in Singapore and has received notice of allowance in the United States.
Predictive A1c is the Company's cornerstone, the first of its kind U.S Food & Drug Administration ("FDA") cleared Diabetes Management Solution that shifts patient self-management to active patient management while providing best practice guidelines and ensuring adherence to care plans. Predictive A1c is owned by Sidney Chan, Chairman and CEO of ALRT. The Company has the right to utilize Predictive A1c pursuant to an informal license with Mr. Chan and expects to acquire the intellectual property in the next 12 months. Final steps have been taken in the United States Patent and Trademark Office for issuance of the US patent for Predictive A1c, and the US patent is expected to grant in the coming weeks. The Company expects Predictive A1c patent applications submitted in other jurisdictions to advance to grant in 2024.
Additionally, ALRT announces the successful completion of its 24-week study led by Singapore General Hospital ("SGH"). A total of 25 insulin-treated patients with type 2 diabetes mellitus were enrolled into the ALRT Diabetes Solution platform. The patients performed twice daily capillary blood glucose checks and weekly glucometer uploads. The platform then provided insulin dose suggestions and alerts to the physicians. All patients experienced a mean drop of 1.2 percent in glycated hemoglobin (HbA1c). The findings from the study validated the significant value that ALRT Diabetes Solution may potentially bring to patients and health care providers. The results were presented at the recent International Diabetes Federation Western Pacific Congress 2023 in Kyoto, Japan, and are expected to be published in the future.
"We are pleased to see the continued success of the ALRT Diabetes Solution from the outcome of this SGH study that replicated the results of our previous clinical trials in Canada and Kansas City, all of which have resulted in a 1.2 percent drop in mean A1c," commented Sidney Chan, Chairman and CEO of ALRT. "The successful conclusion of this study gives ALRT the clinical evidence needed to continue forwarding our efforts in deploying ALRT Diabetes Solution in ASEAN territories. On top of that, receiving the patent grant for Predictive A1c protects our clinically proven effective diabetes management system against would be competitors while securing our competitive advantage over other software platforms."
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA- cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate
dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT and the GluCurve Pet CGM can be found at www.alrt.com and https://www.glucurve.com/Index.
ALRT news: Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
SINGAPORE, Sept. 28, 2023 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCQB: ALRTF), a diabetes management company, announces the patent application titled Method and System of Monitoring a Diabetes Treatment Plan ("Predictive A1c") has been granted in Singapore and has received notice of allowance in the United States.
Predictive A1c is the Company's cornerstone, the first of its kind U.S Food & Drug Administration ("FDA") cleared Diabetes Management Solution that shifts patient self-management to active patient management while providing best practice guidelines and ensuring adherence to care plans. Predictive A1c is owned by Sidney Chan, Chairman and CEO of ALRT. The Company has the right to utilize Predictive A1c pursuant to an informal license with Mr. Chan and expects to acquire the intellectual property in the next 12 months. Final steps have been taken in the United States Patent and Trademark Office for issuance of the US patent for Predictive A1c, and the US patent is expected to grant in the coming weeks. The Company expects Predictive A1c patent applications submitted in other jurisdictions to advance to grant in 2024.
Additionally, ALRT announces the successful completion of its 24-week study led by Singapore General Hospital ("SGH"). A total of 25 insulin-treated patients with type 2 diabetes mellitus were enrolled into the ALRT Diabetes Solution platform. The patients performed twice daily capillary blood glucose checks and weekly glucometer uploads. The platform then provided insulin dose suggestions and alerts to the physicians. All patients experienced a mean drop of 1.2 percent in glycated hemoglobin (HbA1c). The findings from the study validated the significant value that ALRT Diabetes Solution may potentially bring to patients and health care providers. The results were presented at the recent International Diabetes Federation Western Pacific Congress 2023 in Kyoto, Japan, and are expected to be published in the future.
"We are pleased to see the continued success of the ALRT Diabetes Solution from the outcome of this SGH study that replicated the results of our previous clinical trials in Canada and Kansas City, all of which have resulted in a 1.2 percent drop in mean A1c," commented Sidney Chan, Chairman and CEO of ALRT. "The successful conclusion of this study gives ALRT the clinical evidence needed to continue forwarding our efforts in deploying ALRT Diabetes Solution in ASEAN territories. On top of that, receiving the patent grant for Predictive A1c protects our clinically proven effective diabetes management system against would be competitors while securing our competitive advantage over other software platforms."
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA- cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate
dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT and the GluCurve Pet CGM can be found at www.alrt.com and https://www.glucurve.com/Index.
Also, the shreprice is a mirage as we see today. one 50k buy at .03 and the ask is now .0399 with only 29k there. Any real buying will move the price up significantly and quickly. It's a low volume stock so large swings are to be expected and don't reflect real value in my opinion
My assessment has 3 categories, the product, company, and stock.
The Product:
I think the GluCurve Pet CGM is quite ingenious, I have talked to multiple veterinarians and diabetic pet owners and they all say the same thing. A pet CGM is desperately needed because you cant check sugar levels on cats or dogs using a lancet, meter, and test strips. Without a CGM its a guessing game, that's why using human CGMs off label from a pharmacy has become so popular. ALRT is capitalizing on a unique opportunity because they already have a diabetes platform in place for humans, they just had to modify it for animals. By doing so they solve all the problems of using a human CGM because they offer animal specific software to vets and pet owners, sell directly to vets, and support the product. Human CGMs have human software for human patient use, have to be prescribed by a pharmacy, and offer no support for animal use. ALRT is literally selling a one of a kind product to a market that desperately wants it with no real competition.
The Company:
I have incredible respect for the CEO Sidney Chan (the company), most CEOs go public on the OTC markets to sell toxic dilution and rip off shareholders... But Sidney has funded the company himself to the tune of over $20,000,000. I don't think people appreciate that he could have let the company go bankrupt at any time and gone private but he didn't. He could of also sold toxic dilution to pay for expenses but he didn't do that either. Instead he has funded the company himself and through his or his family's trust and backed it up with options to buy common shares as high as .05 each if I remember correctly. That means for him to win, we all have to win.
The Stock:
Because all of us have been invested in ALRT for years I think we have a jaded view where many feel like they are owed a huge return and have lost patience with the stock so the delays this year have killed the excitement. But reading the past 3 PRs from December, June, and August makes me extremely excited. Every PR the sales value of the order goes up, they are launching in Canada direct to clinics at higher margins, and they are relaunching in the US and EU through Covetrus shortly after. They have a better CGM, better manufacturer, and obviously huge demand. Clearly they have had manufacturing issues that have caused delays, but that is outside of their control so I don't blame ALRT for that and it doesn't change my excitement or long term view. When all sorted, the GluCurve seems like a cash cow and the stock price will reflect that in time regardless of current price. In my opinion, the current price is a huge buying opportunity right before they achieve success. I'm not worried about day to day price because if it triples tomorrow I would not sell a share. I'm looking long term for life changing returns not short term for a double up.
I am as bullish on ALRT as I have ever been and I am more confident in the company then ever because I see progress and perseverance and it comes at the CEOs expense not us shareholders. I have no doubt the shareprice will be significantly higher soon so weather that takes a few weeks or a few months I'm not worried about it.
Low-Floater ALRTF news! GluCurve-Pet-CGM $700,000 Canadian-launch August-28th! News is on their website www.alrt.com and a few PR scanners now, but it should start hitting all the major wires soon.
ALR Technologies Announces Canadian Launch Plans for the GluCurve Pet CGM
(August 7th, 2023 -- Singapore) ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTCQB:ALRTF), the diabetes management company, announces plans to launch the GluCurve Pet CGM (“GluCurve”) in Canada during Q3 2023 with a direct to veterinarian clinic sales model through GluCurve.ca. The Canadian website will go live on or before August 28th when the Company expects to begin taking orders. The inventory from the purchase order announced on June 1, 2023 will now be used for the Canadian launch. The quantity of units ordered has been increased and delivery will be spread out between August through October with a projected sales value of $600,000-$700,000.
“We are extremely excited to launch the GluCurve Pet CGM for the estimated 75,000+ diabetic cats and dogs in Canada,” said Joe Stern Head of Animal Health at ALR Technologies SG Ltd. “The Canadian veterinary market is a unique landscape that does not use distributors like the US or EU, providing us the opportunity to sell direct to clinics at very favorable margins. Between the size and nature of the market, and the significant interest we have received from Canadian veterinarians, the decision to supply the GluCurve to Canada was obvious.”
The Company’s CGM hardware supplier is finalizing and converting manufacturing from their 1st generation all-in-one model CGM previously referenced in ALRT’s June 1, 2023 press release, to a 2nd generation all-in-one model CGM expected to be ready for use in Q4 2023 for GluCurve. During this transition, an interim two piece model consisting of a separate sensor and Bluetooth transmitter will be made available in limited quantities to ALRT for the Canadian market. It boasts the same specifications and technological achievements as the 1st generation all-in-one model previously announced.
The quantity of CGM units required for the US and EU markets dictates that ALRT and its distributor defer the launch until the new 2nd generation all-in-one model is available from the Company’s CGM hardware supplier. At which time, the Company will be well positioned to meet market demand with reduced delivery lead-times and significant production availability. GluCurve featuring the all-in-one model CGM hardware will replace the interim two piece model in Canada concurrent with the US and EU launch.
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT and the GluCurve Pet CGM can be found at https://www.alrt.com and https://www.glucurve.com/Index.
News! GluCurve-Pet-CGM Canadian launch Aug-28th, $700,000 sales value on first order! News on the website and a few PR scanners now, should hit all the wires soon.
ALR Technologies Announces Canadian Launch Plans for the GluCurve Pet CGM
(August 7th, 2023 -- Singapore) ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTCQB:ALRTF), the diabetes management company, announces plans to launch the GluCurve Pet CGM (“GluCurve”) in Canada during Q3 2023 with a direct to veterinarian clinic sales model through GluCurve.ca. The Canadian website will go live on or before August 28th when the Company expects to begin taking orders. The inventory from the purchase order announced on June 1, 2023 will now be used for the Canadian launch. The quantity of units ordered has been increased and delivery will be spread out between August through October with a projected sales value of $600,000-$700,000.
“We are extremely excited to launch the GluCurve Pet CGM for the estimated 75,000+ diabetic cats and dogs in Canada,” said Joe Stern Head of Animal Health at ALR Technologies SG Ltd. “The Canadian veterinary market is a unique landscape that does not use distributors like the US or EU, providing us the opportunity to sell direct to clinics at very favorable margins. Between the size and nature of the market, and the significant interest we have received from Canadian veterinarians, the decision to supply the GluCurve to Canada was obvious.”
The Company’s CGM hardware supplier is finalizing and converting manufacturing from their 1st generation all-in-one model CGM previously referenced in ALRT’s June 1, 2023 press release, to a 2nd generation all-in-one model CGM expected to be ready for use in Q4 2023 for GluCurve. During this transition, an interim two piece model consisting of a separate sensor and Bluetooth transmitter will be made available in limited quantities to ALRT for the Canadian market. It boasts the same specifications and technological achievements as the 1st generation all-in-one model previously announced.
The quantity of CGM units required for the US and EU markets dictates that ALRT and its distributor defer the launch until the new 2nd generation all-in-one model is available from the Company’s CGM hardware supplier. At which time, the Company will be well positioned to meet market demand with reduced delivery lead-times and significant production availability. GluCurve featuring the all-in-one model CGM hardware will replace the interim two piece model in Canada concurrent with the US and EU launch.
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT and the GluCurve Pet CGM can be found at https://www.alrt.com and https://www.glucurve.com/Index.
Senseionics has an implantable CGM that requires minor surgery to place under the skin, and then a transmitter has to be attached overtop the skin to transmitter the readings to a phone. It has a ton of problems for humans and even more so for animal use. I dont have it handy but I remember reading a study that was done with it on animals and that did not go well, I believe a number of units stopped working or got lost in the skin.
Senseionics implantable CGMs will never catch on for use in humans or animals in my opinion. They are also thousands of dollars each/
Volume and dollar amount traded has been next to none, but L2 shows 10k at .0425, 110k shares at .05, then 220k at .07 so if any real volume comes through we'll be right back to the .07+ mark...
Big news from ALRTF! $350k PO for their diabetic pet CGM being sold by Covetrus who just got bough out for $4 billion by venture capitalists. Animals health is huge
SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, announces the issuance of a purchase order for the first shipment of second generation CGM hardware used in the GluCurve Pet CGM. The shipment is expected to be delivered to ALRT’s distributor in early Q3 with a sales value of USD $350,000.
“We quickly sold out of inventory during our soft launch in January due to tremendous interest in the GluCurve Pet CGM from veterinarians, pet parents, and various animal health companies. This led us to the decision to switch hardware suppliers in order to accelerate the second generation GluCurve,” said Joe Stern, Head of Animal Health at ALR Technologies SG Ltd. “While the new CGM hardware is technologically impressive, the most prudent reason for the change was manufacturing capabilities and reliability. Our new supplier has proven experience and is able to produce millions of units of CGM hardware per year giving us the ability to conduct a full-scale U.S. launch, E.U. launch, and global launch on our own timeline. In light of the switch, we will not have sales for the first half of 2023, however, this change will give ALRT the opportunity to exceed our previous outlook for full year 2023 revenue and earnings.”
In addition to removing restrictions on production volume and enhancing reliability, the second generation GluCurve is an all-in-one model which increases the ease of application, it has improved accuracy, improved Bluetooth range from 6ft+ to 20ft+, and is a quarter of the size and half the weight of the original model.
A portion of the CGM hardware shipped for the soft launch in January did not meet ALRT’s quality standards which will result in refunds or replacement units. Any replacement units along with current and future orders will be filled with second generation CGM hardware.
Big news from ALRTF! $350k PO for their diabetic pet CGM being sold by Covetrus who just got bough out for $4 billion by venture capitalists. Animals health is huge
SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, announces the issuance of a purchase order for the first shipment of second generation CGM hardware used in the GluCurve Pet CGM. The shipment is expected to be delivered to ALRT’s distributor in early Q3 with a sales value of USD $350,000.
“We quickly sold out of inventory during our soft launch in January due to tremendous interest in the GluCurve Pet CGM from veterinarians, pet parents, and various animal health companies. This led us to the decision to switch hardware suppliers in order to accelerate the second generation GluCurve,” said Joe Stern, Head of Animal Health at ALR Technologies SG Ltd. “While the new CGM hardware is technologically impressive, the most prudent reason for the change was manufacturing capabilities and reliability. Our new supplier has proven experience and is able to produce millions of units of CGM hardware per year giving us the ability to conduct a full-scale U.S. launch, E.U. launch, and global launch on our own timeline. In light of the switch, we will not have sales for the first half of 2023, however, this change will give ALRT the opportunity to exceed our previous outlook for full year 2023 revenue and earnings.”
In addition to removing restrictions on production volume and enhancing reliability, the second generation GluCurve is an all-in-one model which increases the ease of application, it has improved accuracy, improved Bluetooth range from 6ft+ to 20ft+, and is a quarter of the size and half the weight of the original model.
A portion of the CGM hardware shipped for the soft launch in January did not meet ALRT’s quality standards which will result in refunds or replacement units. Any replacement units along with current and future orders will be filled with second generation CGM hardware.
Big Diabetic Pet CGM news from ALRTF who partnered with Covetrus to sell it in the US and EU, Covetrus just got bought out for $4 billion
SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, announces the issuance of a purchase order for the first shipment of second generation CGM hardware used in the GluCurve Pet CGM. The shipment is expected to be delivered to ALRT’s distributor in early Q3 with a sales value of USD $350,000.
“We quickly sold out of inventory during our soft launch in January due to tremendous interest in the GluCurve Pet CGM from veterinarians, pet parents, and various animal health companies. This led us to the decision to switch hardware suppliers in order to accelerate the second generation GluCurve,” said Joe Stern, Head of Animal Health at ALR Technologies SG Ltd. “While the new CGM hardware is technologically impressive, the most prudent reason for the change was manufacturing capabilities and reliability. Our new supplier has proven experience and is able to produce millions of units of CGM hardware per year giving us the ability to conduct a full-scale U.S. launch, E.U. launch, and global launch on our own timeline. In light of the switch, we will not have sales for the first half of 2023, however, this change will give ALRT the opportunity to exceed our previous outlook for full year 2023 revenue and earnings.”
In addition to removing restrictions on production volume and enhancing reliability, the second generation GluCurve is an all-in-one model which increases the ease of application, it has improved accuracy, improved Bluetooth range from 6ft+ to 20ft+, and is a quarter of the size and half the weight of the original model.
A portion of the CGM hardware shipped for the soft launch in January did not meet ALRT’s quality standards which will result in refunds or replacement units. Any replacement units along with current and future orders will be filled with second generation CGM hardware.
Big Diabetic Pet CGM news from ALRTF who partnered with Covetrus to sell it in the US and EU, Covetrus just got bought out for $4 billion
SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, announces the issuance of a purchase order for the first shipment of second generation CGM hardware used in the GluCurve Pet CGM. The shipment is expected to be delivered to ALRT’s distributor in early Q3 with a sales value of USD $350,000.
“We quickly sold out of inventory during our soft launch in January due to tremendous interest in the GluCurve Pet CGM from veterinarians, pet parents, and various animal health companies. This led us to the decision to switch hardware suppliers in order to accelerate the second generation GluCurve,” said Joe Stern, Head of Animal Health at ALR Technologies SG Ltd. “While the new CGM hardware is technologically impressive, the most prudent reason for the change was manufacturing capabilities and reliability. Our new supplier has proven experience and is able to produce millions of units of CGM hardware per year giving us the ability to conduct a full-scale U.S. launch, E.U. launch, and global launch on our own timeline. In light of the switch, we will not have sales for the first half of 2023, however, this change will give ALRT the opportunity to exceed our previous outlook for full year 2023 revenue and earnings.”
In addition to removing restrictions on production volume and enhancing reliability, the second generation GluCurve is an all-in-one model which increases the ease of application, it has improved accuracy, improved Bluetooth range from 6ft+ to 20ft+, and is a quarter of the size and half the weight of the original model.
A portion of the CGM hardware shipped for the soft launch in January did not meet ALRT’s quality standards which will result in refunds or replacement units. Any replacement units along with current and future orders will be filled with second generation CGM hardware.
The December PR said manufacturing was the limiting factor on a bigger launch, so having a new supplier with no restraints is a huge deal in my opinion. $350k for one order means we could should see millions in revenue over the next 6 months. It's also nice that it is an improvement on the CGM hardware itself
News! SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, announces the issuance of a purchase order for the first shipment of second generation CGM hardware used in the GluCurve Pet CGM. The shipment is expected to be delivered to ALRT’s distributor in early Q3 with a sales value of USD $350,000.
“We quickly sold out of inventory during our soft launch in January due to tremendous interest in the GluCurve Pet CGM from veterinarians, pet parents, and various animal health companies. This led us to the decision to switch hardware suppliers in order to accelerate the second generation GluCurve,” said Joe Stern, Head of Animal Health at ALR Technologies SG Ltd. “While the new CGM hardware is technologically impressive, the most prudent reason for the change was manufacturing capabilities and reliability. Our new supplier has proven experience and is able to produce millions of units of CGM hardware per year giving us the ability to conduct a full-scale U.S. launch, E.U. launch, and global launch on our own timeline. In light of the switch, we will not have sales for the first half of 2023, however, this change will give ALRT the opportunity to exceed our previous outlook for full year 2023 revenue and earnings.”
In addition to removing restrictions on production volume and enhancing reliability, the second generation GluCurve is an all-in-one model which increases the ease of application, it has improved accuracy, improved Bluetooth range from 6ft+ to 20ft+, and is a quarter of the size and half the weight of the original model.
A portion of the CGM hardware shipped for the soft launch in January did not meet ALRT’s quality standards which will result in refunds or replacement units. Any replacement units along with current and future orders will be filled with second generation CGM hardware.
Interesting. The 20F states they are releasing a 2nd generation model during or prior to Q3 which makes me think its would be June or July. It also says it was only a portion of the units shipped that are being refunded and that they were covered by the manufacturers warranty.
It also says they are expecting to have the 2nd gen hardware secured in Q2 so that must be why we havent heard an updates yet. They must be in the final stages of the contract, I wonder if that means its a different vendor too?
In January 2023, we collected proceeds of $160,000 in relation to the December 2022 delivery of GluCurve Pet CGM units. These GluCurve Pet CGM units utilized first generation CGM hardware provided by Infinovo. A portion of the CGM hardware supplied to us did not meet the GluCurve Pet CGM specifications for the end users. Accordingly, we will provide either refunds or replacement CGM Hardware units to Covetrus for those units which did not meet the GluCurve Pet CGM specifications. We are working with Covetrus to determine the amount of refund or replacement CGM Hardware units we will be issuing and expect to be offsetting the related cost against a warranty claim from Infinovo. We are evaluating options to launch the second generation CGM Hardware for the GluCurve Pet CGM and expect to have our supply of the second generation CGM Hardware secured in Q2 2023 and the initial shipments occurring during or prior to Q3 2023
I'm here and more excited then ever. Last time I talked to my veterinarian he said the GluCurve Pet CGM created quite a buzz in the veterinary community, an animal specific CGM for is something they have been hoping to get for many years now. He said the prevalence of writing prescriptions for human CGMs is extremely high but the vets dont make money, its inconvenient, and the software is a nightmare to try and get the data for. Basically everything ALRT has said in PRs and on the www.GluCurve.com website... He also said when he tried to order it, it was on back order.
I think JohnGlen said it best, we needt to get off the OTC markets... ALRT announced a partnership with a $4 billion dollar company who has ads for the product as a Covetrus branded exclusive item, sales for Q4 (basically one order in December from what it looks like) was around $150,000 with projections going up from there, and yet no price movement tells you we need a real exchange.
If there is one thing I know about Sidney Chan it's that he plans for the short term, medium term, and long term and he never gives up. We know the product was a hit (sold out), and that there is a huge demand, so at this point I am just patiently waiting for the market to catch up to what is going on at ALRT and for more news from the company on partnerships and sales.
Regardless of if we are trading at .04 cents or $1.00 I am not selling until the full (or close to it) potential is realized which I dont believe will be until next year when the pet CGM has penetrated the global market at a high rate.
That is my hunch, I bet when they uplist to NYSE they will have an underwriter or organization purchase shares at a higher level to sustain the price and set a floor because a $30 million market cap is crazy cheap, its basically getting in at ground floor not to mention the stock will need liquidity and no real player can buy millions of dollars worth in the open market so paying up would make sense for everybody.
GluCurve website is out and looks fantastic, has anybody seen this yet? https://www.glucurve.com/Index
I had to search using the web browser search feature so no worries haha. Guess it makes since to stand out more with the product name so people know what ALRT is all about and they get more traffic
They are on the list under booth #4438 The GluCurve Pet CGM, it's under "T" not "A"
You have good timing, many of us have been invested for years but you're getting in at just the right time. There is no dilution, the company has been funded by the CEO and his family so there is no toxic dilution or new shares hitting the market nor has there ever been.
I actually feel the opposite, I think today proves beyond a reasonable doubt why we need to get off the OTC markets and onto the big boards where sophisticated investors will value ALRT reasonably.
The tradeable float is $6 million, even if the float doubled to 240 million shares (before a R/S) it would still only be $12 million. Nobody is going to short a float that small, it would be unfathomably risky for a very small reward.
Beyond the risk/reward you also have the shareholder base who are holding long term so there would be little to no chance of covering a large short position.
But more importantly, with the partnership, revenue, and growth I cannot imagine a lack of interested from bigger investors. It would also open ALRT up to foreign investors because it's next to impossible for them to trade OTC stocks.
$750k in 4-months with potential upward adjustment and we have 8k shares for $500 in volume?? I don't get it...
Not to mention the PR says sales are going to increase significantly each quarter AND the have an attractive gross profit...
This is literally the best PR I have ever seen from a penny stock.
It’s on yahoo, seeking alpha, benzinga, webull… I dont see it on etrade,TD, WSJ yet but they usually come later.
I’m pretty sure just from the units, I think they have previously said the veterinary platform is free.
$ALRTF announces $750k revenue Dec-March, $.05 with 120M-float
SINGAPORE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM. The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market.
Additionally, the Company announces it anticipates December and fourth quarter of 2022 sales to be in the range of $145,000 and $155,000. The Company expects Q1 2023 sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
“December reflects a turning point for ALRT as we look to close out the fiscal year with our first quarter of meaningful sales, along with an attractive gross profit,” said Sidney Chan, Chairman and CEO of ALRT. “We will be exhibiting the GluCurve Pet CGM at CES January 5th-8th and VMX (Veterinary Meeting and Expo) January 14th-18th which should bolster awareness around the Company and GluCurve. The number of available units will increase quarter over quarter throughout 2023 resulting in a significant rise in sales as it will enable our distribution partner, Covetrus, to launch GluCurve throughout the US, EU, and other key markets.”
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT can be found at www.alrt.com and https://sg.alrt.com.